Collaboration and License Agreements - Additional Information (Detail) - USD ($)	3 Months Ended
Mar. 31, 2026	Mar. 31, 2025
Collaboration And License Arrangement [Line Items]
Collaboration revenue	$ 3,000,000	$ 7,679,000
Elevar [Member] \| Elevar Agreement [Member]
Collaboration And License Arrangement [Line Items]
Collaborative arrangement, purpose	In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement (as amended from time to time, the "Elevar Agreement"), pursuant to which Elevar was granted exclusive global development and commercialization rights for lirafugratinib (RLY-4008), the Company's selective oral small molecule inhibitor of fibroblast growth factor receptor 2 ("FGFR2"). Upon execution of the Elevar Agreement, Elevar is responsible for all further development activities and global commercialization for lirafugratinib in FGFR2-driven cholangiocarcinoma and FGFR2-altered other solid tumors.
License agreement transaction price	$ 18,400,000
Payment for upfront consideration	5,000,000
Payment for transfer active pharmaceutical ingredient and other material	3,400,000
Collaboration revenue	3,000,000	$ 7,700,000
Milestone payment	10,000,000
Elevar [Member] \| Elevar Agreement [Member] \| Maximum [Member]
Collaboration And License Arrangement [Line Items]
Amount receivable upon achievement of regulatory and commercial milestones	$ 485,000,000

Collaboration And License Arrangement [Line Items]

In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement (as amended from time to time, the "Elevar Agreement"), pursuant to which Elevar was granted exclusive global development and commercialization rights for lirafugratinib (RLY-4008), the Company's selective oral small molecule inhibitor of fibroblast growth factor receptor 2 ("FGFR2"). Upon execution of the Elevar Agreement, Elevar is responsible for all further development activities and global commercialization for lirafugratinib in FGFR2-driven cholangiocarcinoma and FGFR2-altered other solid tumors.

5,000,000

Collaboration revenue

3,000,000

$ 7,700,000

Amount receivable upon achievement of regulatory and commercial milestones

$ 485,000,000